What is ICOS?
The International CardiOncology Society (www.cardioncology.com)

• It is a group of interested and committed medical providers that hope to eliminate cardiac disease as a barrier to cancer treatment
A Special Issue of Progress in Cardiovascular Diseases:
War on Cancer Produces Collateral Damage to the Heart

This issue of Progress in Cardiovascular Disease was inspired by the very successful third International Symposium of the Cardiology Oncology Partnership, which was held in September 2009 in Milan, Italy. This meeting marked the inauguration of the International CardiOncoSociety, an international society responding to the need for cooperation between these medical disciplines.

“The recent recognition of the frequent collateral damage of the heart from many of the newer chemotherapeutic agents, as well as the classic anthracyclines, and the importance of this to management of the cancer, should spur the acquisition of cardiac outcomes data and ultimately trigger the development of specific evidence-based practice guidelines to keep the heart from interfering with the war on cancer,” commented Dr. Mann and Dr. Krone.

The International CardiOncoSociety (ICOS) was constituted January 2009 by Doctor Carlo Cipolla, European Institute of Oncology, Milano, Italy, accordingly to Doctor Daniel Lenihan, MD Anderson Cancer Center, Houston, Texas, USA. 

Read more . . .
# BOARD OF DIRECTORS

<table>
<thead>
<tr>
<th>Position</th>
<th>American Branch</th>
<th>European Branch</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Daniel Lenihan</td>
<td>Carlo Cipolla</td>
</tr>
<tr>
<td>Vice President</td>
<td>Charlie Porter</td>
<td>Daniela Cardinale</td>
</tr>
<tr>
<td>Scientific Secretary</td>
<td>Aarif Khakoo</td>
<td>Giuseppe Curigliano</td>
</tr>
<tr>
<td>Scientific Committee</td>
<td>Louis Constine</td>
<td>Fabio Ciceri</td>
</tr>
<tr>
<td></td>
<td>Ron Krone</td>
<td>Tommaso De Pas</td>
</tr>
<tr>
<td></td>
<td>Bonnie Ky</td>
<td>Aaron Goldhirsch</td>
</tr>
<tr>
<td></td>
<td>Apostolia Tsimeridou</td>
<td>Piergiuseppe Pelicci</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maria Teresa Sandri</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thomas Suter</td>
</tr>
<tr>
<td>Education/Guideline Committee</td>
<td>Joseph Carver</td>
<td>Adriana Albini</td>
</tr>
<tr>
<td></td>
<td>Debra Friedman</td>
<td>Alessandro Colombo</td>
</tr>
<tr>
<td>In Charge for ICOS in Asia</td>
<td>Gouri Shankar Bhattacharyya</td>
<td></td>
</tr>
<tr>
<td>Legal Assistance</td>
<td></td>
<td>Franco Del Curto</td>
</tr>
<tr>
<td>Treasurer</td>
<td></td>
<td>Flavio Pirola</td>
</tr>
<tr>
<td>Website</td>
<td></td>
<td>Anna Eggertz</td>
</tr>
<tr>
<td>Fund Raising</td>
<td></td>
<td>Natalia Pozzi</td>
</tr>
</tbody>
</table>
From the Scientist Perspective, Many Mechanisms for Cell Survival and Repair are Common Between the Heart and Cancer Cells
Douglas B. Sawyer, MD, PhD 5–8

Thrombosis in Cancer Patients: What are the treatments and the challenges?
Agnes Lee, MD, MSc, FRCPC 8–13

Cardiac Biomarkers and Preclinical Detection of Cardiotoxicity
Daniela Cardinale, MD, PhD 13–18

Common Terminology Criteria for Adverse Events and the Cardiovascular System
Scott C. Remick, MD 18–20

Cardiac Issues in Cancer Patients: Are we responding appropriately?
Ronald M. Witteles, MD 20–24

Molecular Basis of Cardiotoxicity May Lead to Cardiovascular Drug Development
Aarif Y. Khakoo, MD, MBA 25–28

PREDICT Trial: Prospective Point of Care Cardiac Biomarkers to Detect Cardiotoxicity
Daniel J. Lenihan, MD 28–31

Neuregulin in Heart Failure: An Upstream Effect of ERBB2 Signaling
Carrie A. Gelberg, MD 32–35

Multicenter Registry for CV Events During Cancer Therapy
Bonnie Ky, MD, MSCE 36–39

Amyloidosis: A Disease all Cardiologists Should Know About
David C. Selvin, MD, PhD 39–45

Hypertension and Cardiac Issues From the Perspective of the Practitioner
Michael J. Fisch, MD, MPH 45–48

Is Preventing and Optimally Treating Heart Failure in Cancer Patients a Reasonable Goal?
JoAnn A. Lindenfeld, MD 48–51
Recent Publications and accomplishments

• Progress in Cardiovascular Diseases (Vol. 53, No. 2, Sept/Oct 2010, Elsevier)
• Heart Failure Clinics (July 2011 issue)
• Many manuscripts in high profile journals in the past 2 years (>10)
• Initiated 2 new multicenter studies
• Multicenter Registry for Cardiotoxicity is in progress
• Many presentations and focused sessions at international meetings
ICOS goals:

• Define cardiovascular risk assessment
• Integrate necessary sophisticated cardiac testing during oncology research into reported findings
• Explore optimal screening techniques being mindful of practical issues
• Standardize definitions for cardiac-related events during chemotherapy
• Contribute to the creation of an international database
• Promoting prevention of heart failure and other major cardiac events during cancer treatment
• Active management of preexisting cardiac disease by a cardiologist can promote the most effective cancer therapy
• Understanding expected clinical outcomes for each discipline to have shared decision making
Flash forward to 2025:
All the cardiologists, oncologists, and primary MDs of the world will have learned that for the optimal care of cancer patients, they enjoy working together.